Degenerative disorders such as Alzheimer's disease have acquired critical relevance, given the larger proportion of aging population in the modern society. Since the pathological changes associated with neurodegeneration (such as beta-amyloid deposits, neurofibrillary tangles, and decreased metabolic activity) often precede clinical disease by several decades, early identification of these changes is of paramount importance. Three different ligands have been reported recently, all of them with the ability to detect intracerebral beta-amyloid deposition with high accuracy using PET radiotracer technology: [18F] FDDNP (Small et al. 2006), [11C] PIB (Pittsburgh Compound-B) (Klunk et al. 2004), and [11C] SB (Ono et al. 2003). Such compounds have potential clinical applications in that they may help identify patients with mild cognitive impairment (MCI) who are at increased risk of converting to dementia (Mathis et al. 2005).
Was this article helpful?